Kiniksa Reports Q1 2026: Significant Growth in ARCALYST Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy KNSA?
Source: Newsfilter
- Significant Revenue Growth: Kiniksa reported Q1 2026 net product revenue of $214.3 million for ARCALYST, reflecting a 56% year-over-year increase, indicating strong market demand and adoption in the cardiovascular treatment sector.
- Sales Guidance Raised: The company has increased its 2026 ARCALYST net sales guidance from $900-$920 million to $930-$945 million, driven by growth in both new and repeat prescribers, providing robust momentum for the remainder of the year.
- Strong Cash Position: As of March 31, 2026, Kiniksa reported a cash balance of $468.1 million with no debt, ensuring financial flexibility for future clinical trials and product development initiatives.
- R&D Progress on Track: KPL-387's Phase 2 clinical trial data is expected in the second half of 2026, with plans to initiate the Phase 3 pivotal trial by year-end, demonstrating the company's ongoing commitment to innovative drug development and strategic positioning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KNSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KNSA
Wall Street analysts forecast KNSA stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 56.930
Low
48.00
Averages
53.50
High
60.00
Current: 56.930
Low
48.00
Averages
53.50
High
60.00
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kiniksa Pharmaceuticals International (KNSA.US) Officer Plans to Sell $3.14 Million in Common Stock via Form 144
Stock Sale Announcement: Paolini John F. intends to sell 58,424 shares of Kiniksa Pharmaceuticals International on May 1, with a total market value of approximately $3.14 million.
Reduction in Shareholding: Since March 2, 2026, Paolini John F. has reduced his shareholding in Kiniksa Pharmaceuticals International by 40,000 shares, valued at around $1.79 million.
See More
Enphase Energy Drops as Solar Demand Weakens
- Earnings Decline: Enphase Energy reported a 31% year-over-year drop in non-GAAP earnings per share for Q1, leading to a more than 10% decline in pre-market trading, highlighting significant challenges in the U.S. market amid tariff costs and oil-centric energy policies.
- International Market Expansion: Despite domestic struggles, CEO Kothandaraman noted healthy double-digit growth in battery demand across Europe, which is expected to drive revenue growth; however, to combat competition, the company plans to reduce distributor prices for batteries by approximately 10% in May.
- Revenue Outlook: Management anticipates Q2 revenue between $280 million and $310 million, following Q1 revenue of $282.9 million, while maintaining non-GAAP gross margins between 44% and 47%, indicating confidence in the commercialization of next-generation products.
- Intensifying Market Competition: With a prior 20% price reduction on microinverters implemented last December, the upcoming price adjustments may impact short-term margins but could pave the way for long-term market share gains, reflecting the company's adaptability in the rapidly evolving solar market.
See More
Kiniksa Pharmaceuticals Reports Strong Q1 Earnings, Shares Surge
- Strong Performance: Kiniksa Pharmaceuticals' inaugural Q1 earnings report for 2026 revealed revenue exceeding $214 million, a significant increase from last year's under $138 million, convincingly beating analyst expectations of $207 million, showcasing the company's robust performance in the biotech sector.
- Net Income Doubles: Under GAAP, Kiniksa's net income more than doubled from $8.5 million in Q1 2025 to $22.6 million, with earnings per share reaching $0.27, significantly surpassing the analyst forecast of $0.21, reflecting a marked improvement in the company's profitability.
- Product Success Drives Growth: The recent approval of Arcalyst, particularly for the heart condition pericarditis, has been a key driver of Kiniksa's popularity, prompting management to raise its 2026 net sales forecast to between $930 million and $945 million, indicating strong market demand for the drug.
- Positive Market Reaction: Following the earnings release, Kiniksa's stock surged nearly 24%, bringing its market capitalization to $3.3 billion, demonstrating investor confidence in the company's future growth potential, especially regarding the development of multiple indications for its single product.
See More
Kiniksa Pharmaceuticals Reports Strong Sales Growth
- Sales Performance Surge: Kiniksa Pharmaceuticals reported first-quarter sales of over $214 million for its drug Arcalyst, marking a significant increase from last year's $138 million, indicating strong market demand and product acceptance.
- Net Income Doubling: Under GAAP, Kiniksa's net income more than doubled from $8.5 million in Q1 2025 to $22.6 million ($0.27 per share), surpassing analyst expectations of $0.21, reflecting a notable improvement in profitability.
- Sales Forecast Upgrade: Management raised the 2026 net sales guidance for Arcalyst from $900 million to $920 million to a new range of $930 million to $945 million, demonstrating confidence in the drug's market potential following its recent approval for heart disorder pericarditis.
- Positive Market Reaction: Following the release of its inaugural 2026 earnings report, Kiniksa's stock surged nearly 24% during the trading session, showcasing strong investor confidence in the company's growth prospects and further solidifying its position in the biotech sector.
See More
Kiniksa Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Sales Growth: Kiniksa Pharmaceuticals reported Q1 2026 ARCALYST sales of $214.3 million, reflecting a 56% year-over-year increase, indicating a growing market acceptance that is expected to further drive overall revenue growth.
- Revenue Guidance Raised: The company has raised its full-year 2026 revenue guidance from $900 million to $920 million to a new range of $930 million to $945 million, reflecting management's confidence in future performance, particularly with the increase in new prescribers.
- Strong Cash Flow: Net income surged to $22.6 million in Q1, with a cash balance of $468.1 million, demonstrating the company's ability to maintain positive cash flow while continuing to invest in R&D, thereby enhancing its financial stability.
- New Marketing Initiatives: Kiniksa launched a direct-to-consumer campaign called “Heart's Home” aimed at increasing patient awareness of ARCALYST, especially given that only 14% of recurrent pericarditis patients are currently aware of the drug, which will help expand market share.
See More
Kiniksa Pharmaceuticals Exceeds Q1 Expectations and Raises Outlook
- Strong Performance: Kiniksa Pharmaceuticals reported $214.3 million in net product revenue for Q1 2026, representing a ~56% year-over-year increase and exceeding consensus estimates by $8.21 million, highlighting the robust market performance of its heart disease therapy, Arcalyst.
- Prescription Growth: Since the launch of Arcalyst, over 4,550 prescribers have issued prescriptions, with growth observed in both new and repeat prescribers during Q1, providing positive momentum for the company's performance, as noted by CEO Sanj Patel.
- Upgraded Full-Year Outlook: Kiniksa raised its full-year net product revenue guidance to $930 million - $945 million, up from the previous forecast of $900 million - $920 million, reflecting confidence in the continued growth of Arcalyst.
- Enhanced Profitability: The company reported a net income of $22.6 million, representing a ~166% year-over-year growth, with GAAP EPS of $0.27 beating consensus by $0.09, indicating a significant improvement in profitability.
See More
Kiniksa Pharmaceuticals International (KNSA.US) Officer Plans to Sell $3.14 Million in Common Stock via Form 144
Stock Sale Announcement: Paolini John F. intends to sell 58,424 shares of Kiniksa Pharmaceuticals International on May 1, with a total market value of approximately $3.14 million.
Reduction in Shareholding: Since March 2, 2026, Paolini John F. has reduced his shareholding in Kiniksa Pharmaceuticals International by 40,000 shares, valued at around $1.79 million.
See More
Enphase Energy Drops as Solar Demand Weakens
- Earnings Decline: Enphase Energy reported a 31% year-over-year drop in non-GAAP earnings per share for Q1, leading to a more than 10% decline in pre-market trading, highlighting significant challenges in the U.S. market amid tariff costs and oil-centric energy policies.
- International Market Expansion: Despite domestic struggles, CEO Kothandaraman noted healthy double-digit growth in battery demand across Europe, which is expected to drive revenue growth; however, to combat competition, the company plans to reduce distributor prices for batteries by approximately 10% in May.
- Revenue Outlook: Management anticipates Q2 revenue between $280 million and $310 million, following Q1 revenue of $282.9 million, while maintaining non-GAAP gross margins between 44% and 47%, indicating confidence in the commercialization of next-generation products.
- Intensifying Market Competition: With a prior 20% price reduction on microinverters implemented last December, the upcoming price adjustments may impact short-term margins but could pave the way for long-term market share gains, reflecting the company's adaptability in the rapidly evolving solar market.
See More
Kiniksa Pharmaceuticals Reports Strong Q1 Earnings, Shares Surge
- Strong Performance: Kiniksa Pharmaceuticals' inaugural Q1 earnings report for 2026 revealed revenue exceeding $214 million, a significant increase from last year's under $138 million, convincingly beating analyst expectations of $207 million, showcasing the company's robust performance in the biotech sector.
- Net Income Doubles: Under GAAP, Kiniksa's net income more than doubled from $8.5 million in Q1 2025 to $22.6 million, with earnings per share reaching $0.27, significantly surpassing the analyst forecast of $0.21, reflecting a marked improvement in the company's profitability.
- Product Success Drives Growth: The recent approval of Arcalyst, particularly for the heart condition pericarditis, has been a key driver of Kiniksa's popularity, prompting management to raise its 2026 net sales forecast to between $930 million and $945 million, indicating strong market demand for the drug.
- Positive Market Reaction: Following the earnings release, Kiniksa's stock surged nearly 24%, bringing its market capitalization to $3.3 billion, demonstrating investor confidence in the company's future growth potential, especially regarding the development of multiple indications for its single product.
See More
Kiniksa Pharmaceuticals Reports Strong Sales Growth
- Sales Performance Surge: Kiniksa Pharmaceuticals reported first-quarter sales of over $214 million for its drug Arcalyst, marking a significant increase from last year's $138 million, indicating strong market demand and product acceptance.
- Net Income Doubling: Under GAAP, Kiniksa's net income more than doubled from $8.5 million in Q1 2025 to $22.6 million ($0.27 per share), surpassing analyst expectations of $0.21, reflecting a notable improvement in profitability.
- Sales Forecast Upgrade: Management raised the 2026 net sales guidance for Arcalyst from $900 million to $920 million to a new range of $930 million to $945 million, demonstrating confidence in the drug's market potential following its recent approval for heart disorder pericarditis.
- Positive Market Reaction: Following the release of its inaugural 2026 earnings report, Kiniksa's stock surged nearly 24% during the trading session, showcasing strong investor confidence in the company's growth prospects and further solidifying its position in the biotech sector.
See More
Kiniksa Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Sales Growth: Kiniksa Pharmaceuticals reported Q1 2026 ARCALYST sales of $214.3 million, reflecting a 56% year-over-year increase, indicating a growing market acceptance that is expected to further drive overall revenue growth.
- Revenue Guidance Raised: The company has raised its full-year 2026 revenue guidance from $900 million to $920 million to a new range of $930 million to $945 million, reflecting management's confidence in future performance, particularly with the increase in new prescribers.
- Strong Cash Flow: Net income surged to $22.6 million in Q1, with a cash balance of $468.1 million, demonstrating the company's ability to maintain positive cash flow while continuing to invest in R&D, thereby enhancing its financial stability.
- New Marketing Initiatives: Kiniksa launched a direct-to-consumer campaign called “Heart's Home” aimed at increasing patient awareness of ARCALYST, especially given that only 14% of recurrent pericarditis patients are currently aware of the drug, which will help expand market share.
See More
Kiniksa Pharmaceuticals Exceeds Q1 Expectations and Raises Outlook
- Strong Performance: Kiniksa Pharmaceuticals reported $214.3 million in net product revenue for Q1 2026, representing a ~56% year-over-year increase and exceeding consensus estimates by $8.21 million, highlighting the robust market performance of its heart disease therapy, Arcalyst.
- Prescription Growth: Since the launch of Arcalyst, over 4,550 prescribers have issued prescriptions, with growth observed in both new and repeat prescribers during Q1, providing positive momentum for the company's performance, as noted by CEO Sanj Patel.
- Upgraded Full-Year Outlook: Kiniksa raised its full-year net product revenue guidance to $930 million - $945 million, up from the previous forecast of $900 million - $920 million, reflecting confidence in the continued growth of Arcalyst.
- Enhanced Profitability: The company reported a net income of $22.6 million, representing a ~166% year-over-year growth, with GAAP EPS of $0.27 beating consensus by $0.09, indicating a significant improvement in profitability.
See More
